Clene Nanomedicine
Clinical trials sponsored by Clene Nanomedicine, explained in plain language.
-
New hope for ALS patients: experimental drug CNM-Au8 now available through expanded access
Disease control TEMPORARILY_NOT_AVAILABLEThis program provides early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Participants must be 18 or older and have a confirmed ALS diagnosis. The goal is to offer treatment to those who cannot join…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gold nanoparticles offered to ALS patients in expanded access program
Disease control NO_LONGER_AVAILABLEThis program provides CNM-Au8, a suspension of gold nanocrystals, to up to 300 people with ALS. The main goal is to give access to the drug and monitor safety, not to test if it works. Participants must have a confirmed ALS diagnosis and be at least 18 years old.
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New MS drug candidate made available to patients before approval
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is designed for people who have no other treatment options. The goal is to provide the drug while researchers continue to study its safety and effectivenes…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gold nanocrystals aim to slow ALS in new trial
Disease control OngoingThis study is an open-label extension for people with early amyotrophic lateral sclerosis (ALS) who completed a previous placebo-controlled trial. Participants will take a daily oral dose of CNM-Au8, a suspension of gold nanocrystals, to see if it safely slows disease progression…
Phase: PHASE2 • Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC